Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Other solid neoplasm 1

Conditions

Carcinoma, Hepatocellular 3Neoplasms 1

Interventions

Gemcitabine 302Fluorouracil 296Oxaliplatin 269Bevacizumab 267Capecitabine 233Leucovorin 229pembrolizumab 215Irinotecan 185Cisplatin 142Cetuximab 142Nivolumab 131Paclitaxel 117130-nm albumin-bound paclitaxel 117Sorafenib 86Albumin-Bound Paclitaxel 75Docetaxel 65regorafenib 64atezolizumab 64IFL protocol 61Folfox protocol 61Trastuzumab 55Panitumumab 47durvalumab 46Ramucirumab 43Injections 43Sunitinib 41Drug Therapy 41Carboplatin 40trifluridine tipiracil drug combination 38lenvatinib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × ascrinvacumab × Gastrointestinal × Clear all
NCT05178043 2024-02-22

GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma

Suzhou Kintor Pharmaceutical Inc,

Phase 2 Unknown
5 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT01337050 2015-10-28

Asian Phase I Study Of PF-03446962

Pfizer

Phase 1 Completed
36 enrolled 24 charts
Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

NCT01911273 2015-10-28

A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer

Pfizer

Phase 2 Terminated
3 enrolled 4 charts
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡